Standout Papers
- Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure (2020)
- A Self-Fulfilling Prophecy (2002)
- Adipokines: molecular links between obesity and atheroslcerosis (2005)
- SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review (2018)
- Acute Spinal Cord Injury, Part I: Pathophysiologic Mechanisms (2001)
- New Markers of Inflammation and Endothelial Cell Activation (2003)
- Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors (2020)
- Resistin Promotes Endothelial Cell Activation (2003)
- Clinical and Pathophysiological Implications of a Bicuspid Aortic Valve (2002)
- Endothelin Antagonism and Interleukin-6 Inhibition Attenuate the Proatherogenic Effects of C-Reactive Protein (2002)
- Endothelial cell control of thrombosis (2015)
- Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease (2019)
- Valve-Related Hemodynamics Mediate Human Bicuspid Aortopathy (2015)
- Aortic Dilatation in Patients with Bicuspid Aortic Valve (2014)
- Empagliflozin Increases Cardiac Energy Production in Diabetes (2018)
- Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function (2020)
- Targeting cardiovascular inflammation: next steps in clinical translation (2020)
- Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of symptomatic severe aortic stenosis: an updated meta-analysis (2019)
- Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status (2020)
- GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes (2022)
- Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction (2021)
- Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial (2024)
- Semaglutide and NT-proBNP in Obesity-Related HFpEF (2024)
- Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial (2025)
Immediate Impact
1 by Nobel laureates 1 from Science/Nature 69 standout
Citing Papers
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
2025 Standout
Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials
2024 Standout
Works of Subodh Verma being referenced
Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial
2024 Standout
Semaglutide and NT-proBNP in Obesity-Related HFpEF
2024 Standout
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Subodh Verma | 13268 | 8658 | 7981 | 628 | 31.0k | |
| Jacques Genest | 12801 | 10316 | 15748 | 704 | 39.5k | |
| Eberhard Ritz | 13530 | 9208 | 5986 | 926 | 43.6k | |
| Georg Nickenig | 14248 | 3022 | 6718 | 712 | 28.8k | |
| Toshio Ogihara | 9551 | 5926 | 6244 | 886 | 31.4k | |
| Steve E. Humphries | 9743 | 9792 | 13992 | 860 | 41.5k | |
| Ulf dé Fairé | 13323 | 7940 | 4284 | 379 | 29.7k | |
| James R. Sowers | 15126 | 14251 | 6310 | 681 | 41.2k | |
| Anders Hamsten | 7767 | 8095 | 6327 | 386 | 29.7k | |
| James T. Willerson | 20757 | 3951 | 16670 | 628 | 47.0k | |
| Mark E. Cooper | 12490 | 17386 | 5789 | 506 | 47.5k |
All Works
Login with ORCID to disown or claim papers
Loading papers...